TY - JOUR
T1 - The combination of high uric acid and high C-reactive protein increased the risk of cardiovascular disease
T2 - A 15-year prospective cohort study
AU - Li, Na
AU - Wu, Shouling
AU - Shu, Rong
AU - Song, Haicheng
AU - Wang, Jierui
AU - Chen, Shuohua
AU - Yang, Wenhao
AU - Wang, Guodong
AU - Yang, Jingtao
AU - Yang, Xuemei
AU - Tse, Gary
AU - Zhang, Nan
AU - Cui, Liufu
AU - Liu, Tong
N1 - Publisher Copyright:
© 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University
PY - 2024/6
Y1 - 2024/6
N2 - Background and aims: Uric acid (UA) and C-reactive protein (CRP) may interact synergistically to accelerate the initiation and progression of cardiovascular disease (CVD). This study investigated the effects of a combination of high UA and high CRP on the risks of CVD. Methods and results: A total of 90,270 participants recruited from the Kailuan study were included, who were divided into four groups according to the presence/absence of hyperuricemia and inflammation. Cox regression was applied to evaluate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) of CVD. C-statistics, net classification index (NRI), and integrated discrimination improvement (IDI) were used to compare the incremental predictive of UA, CRP, and their combined effects on CVD. Mediation analysis was to explore the impact of CRP on the association between UA and CVD. Over a median follow-up of 14.95 years, we identified 11398 incident CVD cases. Compared to the low UA/low CRP group, the high UA/low CRP, low UA/high CRP and high UA/high CRP groups showed progressively higher risks of CVD, HR (95% CI): 1.18(1.10–1.27), 1.27(1.21–1.33) and 1.50 (1.33–1.69), respectively. The incorporation of UA and CRP into the traditional China-PAR model led to improvement in the C-statistic, NRI, and IDI, and was better than incorporation of either UA or CRP alone. Mediation analysis showed that CRP mediated the association between UA and CVD, accounting for 11.57% of the total effects. Conclusions: High UA/high CRP is associated with increased risks of CVD. Incorporation of both UA and CRP provided additional value for risk stratification.
AB - Background and aims: Uric acid (UA) and C-reactive protein (CRP) may interact synergistically to accelerate the initiation and progression of cardiovascular disease (CVD). This study investigated the effects of a combination of high UA and high CRP on the risks of CVD. Methods and results: A total of 90,270 participants recruited from the Kailuan study were included, who were divided into four groups according to the presence/absence of hyperuricemia and inflammation. Cox regression was applied to evaluate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) of CVD. C-statistics, net classification index (NRI), and integrated discrimination improvement (IDI) were used to compare the incremental predictive of UA, CRP, and their combined effects on CVD. Mediation analysis was to explore the impact of CRP on the association between UA and CVD. Over a median follow-up of 14.95 years, we identified 11398 incident CVD cases. Compared to the low UA/low CRP group, the high UA/low CRP, low UA/high CRP and high UA/high CRP groups showed progressively higher risks of CVD, HR (95% CI): 1.18(1.10–1.27), 1.27(1.21–1.33) and 1.50 (1.33–1.69), respectively. The incorporation of UA and CRP into the traditional China-PAR model led to improvement in the C-statistic, NRI, and IDI, and was better than incorporation of either UA or CRP alone. Mediation analysis showed that CRP mediated the association between UA and CVD, accounting for 11.57% of the total effects. Conclusions: High UA/high CRP is associated with increased risks of CVD. Incorporation of both UA and CRP provided additional value for risk stratification.
KW - C-reactive protein
KW - Cardiovascular disease
KW - Combined exposure
KW - Mediation analysis
KW - Uric acid
UR - http://www.scopus.com/inward/record.url?scp=85188132288&partnerID=8YFLogxK
U2 - 10.1016/j.numecd.2024.01.027
DO - 10.1016/j.numecd.2024.01.027
M3 - Article
C2 - 38503620
AN - SCOPUS:85188132288
SN - 0939-4753
VL - 34
SP - 1508
EP - 1517
JO - Nutrition, Metabolism and Cardiovascular Diseases
JF - Nutrition, Metabolism and Cardiovascular Diseases
IS - 6
ER -